Precision for Medicine, a prominent figure in biomarker-driven clinical research and development for life sciences companies, has made an announcement today regarding its acquisition of Algorics, a swiftly growing provider of clinical technologies and biometrics services to the biopharmaceutical industry. This move aims to strengthen Precision for Medicine's presence in the Asia-Pacific region and enhance its global capabilities in clinical data management, biostatistics, and programming.

Precision for Medicine, emphasized the strategic importance of the acquisition, stating, "The addition of Algorics expands our suite of clinical technologies, empowering our project teams to better monitor and advise sponsors on trial performance. It also amplifies our capacity to handle diverse datasets with agility and scale." Baig highlighted Algorics' team of biostatisticians and data scientists as key assets, reinforcing Precision's operational presence in the crucial Asia-Pacific region.

Algorics brings two innovative clinical technologies to Precision for Medicine. MetaVate, a robust metadata transformation engine, streamlines data conversion to meet industry standards and accelerate submission readiness. This strengthens the statistical programming and biostatistics services offered to clients. The second technology, Clarity, is a platform for clinical intelligence, risk-based monitoring, and study performance management. By centralizing trial data and providing key insights, Clarity enables timely decision-making, enhances trial outcomes, and simplifies risk management throughout study execution.

Algorics and now Senior Vice President of Biometrics at Precision for Medicine, expressed pride in joining forces with Precision. She stated, "The integration of our technologies and staff will unlock scale and technological advantages, enabling us to better serve clients globally with comprehensive solutions spanning the entire clinical research continuum."

In summary, the acquisition of Algorics marks a significant step for Precision for Medicine, reinforcing its position as a leader in biomarker-driven clinical research and expanding its capabilities to deliver enhanced outcomes for clients worldwide.

 

Source: prnewswire.com

Report Abuse